drugset / Trial / NCT02007941

Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects

NCT02007941

Phase 1 Completed 28 enrolled Chong Kun Dang Pharmaceutical
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess between the renal impaired patients and normal renal function subjects comparetive evaluation to Pharmacokinetics after CKD-501 Future, When prescription CKD-501 to renal impaired patient, It will be guidelines to provide a basis of instructions.

Timeline

Start
2014-04
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Lobeglitazone Small molecule 0.5 mg